These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32363211)

  • 1. Real-world Experience of Bezlotoxumab for Prevention of
    Hengel RL; Ritter TE; Nathan RV; Van Anglen LJ; Schroeder CP; Dillon RJ; Marcella SW; Garey KW
    Open Forum Infect Dis; 2020 Apr; 7(4):ofaa097. PubMed ID: 32363211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
    Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
    Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
    Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
    Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
    Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
    Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezlotoxumab in Patients with a Primary
    Granata G; Schiavone F; Pipitone G
    Antibiotics (Basel); 2022 Oct; 11(11):. PubMed ID: 36358149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Bezlotoxumab for Prevention of Recurrent
    Johnson TM; Howard AH; Miller MA; Allen LL; Huang M; Molina KC; Bajrovic V
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab294. PubMed ID: 34262988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis.
    Mohamed MFH; Ward C; Beran A; Abdallah MA; Asemota J; Kelly CR
    J Clin Gastroenterol; 2024 Apr; 58(4):389-401. PubMed ID: 37395627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
    Madoff SE; Urquiaga M; Alonso CD; Kelly CP
    Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.
    Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M
    Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.
    Johnson S; Citron DM; Gerding DN; Wilcox MH; Goldstein EJC; Sambol SP; Best EL; Eves K; Jensen E; Dorr MB
    Clin Infect Dis; 2021 Nov; 73(9):e2616-e2624. PubMed ID: 32735653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Impairment,
    Golan Y; DuPont HL; Aldomiro F; Jensen EH; Hanson ME; Dorr MB
    Open Forum Infect Dis; 2020 Jul; 7(7):ofaa248. PubMed ID: 32685606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.
    Yee KL; Kleijn HJ; Zajic S; Dorr MB; Wrishko RE
    J Pharmacokinet Pharmacodyn; 2020 Apr; 47(2):121-130. PubMed ID: 32048107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of
    de la Villa S; Herrero S; Muñoz P; Rodríguez C; Valerio M; Reigadas E; Álvarez-Uría A; Alcalá L; Marín M; Olmedo M; Kestler M; Chamorro E; Bouza E
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad028. PubMed ID: 36776780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.